ID

19904

Description

The purpose of this study is to determine the safety and efficacy of natalizumab in the treatment of individuals who have been diagnosed with relapsing remitting multiple sclerosis (MS). It is hoped that natalizumab will prevent certain types of white blood cells from moving out of the bloodstream into organs, including the brain, that are being damaged by autoimmune disease (a disease in which the body's own immune system attacks certain organs). These white blood cells are thought to cause inflammation that can result in lesions (small areas of damage) in the brain. These lesions are thought to be the cause of relapses and disability in MS.

Keywords

Versions (1)
  1. 1/30/17 1/30/17 -
Uploaded on

January 30, 2017

DOI

To request one please log in.

License

Creative Commons BY-NC 3.0
Model comments :

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Back to model comments
Itemgroup comments for :

Item comments for :

In order to download data models you must be logged in. Please log in or register for free.

Telephone Visit CRFs Multiple Sclerosis Tysabri NCT00027300

English

Telephone Visit CRFs Multiple Sclerosis Tysabri NCT00027300

1 forms  
Telephone Visit
Description

Telephone Visit

Alias
UMLS CUI-1
C0178941
contact not made
Description

contact not made

Data type

boolean

Alias
UMLS CUI [1]
C1705415
date of contact
Description

date of contact

Data type

date

Alias
UMLS CUI [1]
C0805839
Person contacted
Description

person contacted

Data type

text

Alias
UMLS CUI [1]
C0337611
If other, specify:
Description

other person contacted

Data type

text

Alias
UMLS CUI [1,1]
C0337611
UMLS CUI [1,2]
C3146298
Since the subject was last contacted, has the subject experienced any new or continuing adverse events? (If Yes, please record adverse event(s) in the CRF)
Description

adverse event

Data type

boolean

Alias
UMLS CUI [1]
C0877248
Since the subject was last contacted, has the subject received any concomitant medications? (Includes IV steroid therapy and alternate MS therapy. If Yes, please record concomitant medications in the CRF)
Description

concomitant medication

Data type

boolean

Alias
UMLS CUI [1]
C2347852
Back to the top of the page

Similar models

Telephone Visit CRFs Multiple Sclerosis Tysabri NCT00027300

1 forms
Name
Type
Description | Question | Decode (Coded Value)
Data type
Alias
Item Group
Telephone Visit
C0178941 (UMLS CUI-1)
contact not made
Item
contact not made
boolean
C1705415 (UMLS CUI [1])
date of contact
Item
date of contact
date
C0805839 (UMLS CUI [1])
Item
Person contacted
text
C0337611 (UMLS CUI [1])
person contacted
Code List
Person contacted
CL Item
Subject (Subject)
CL Item
Other (Other)
other person contacted
Item
If other, specify:
text
C0337611 (UMLS CUI [1,1])
C3146298 (UMLS CUI [1,2])
adverse event
Item
Since the subject was last contacted, has the subject experienced any new or continuing adverse events? (If Yes, please record adverse event(s) in the CRF)
boolean
C0877248 (UMLS CUI [1])
concomitant medication
Item
Since the subject was last contacted, has the subject received any concomitant medications? (Includes IV steroid therapy and alternate MS therapy. If Yes, please record concomitant medications in the CRF)
boolean
C2347852 (UMLS CUI [1])
Back to the top of the page 

Contact

Please use this form for feedback, questions and suggestions for improvements.

Fields marked with * are required.

Help

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial